Common Name | IUPAC NameIdentification Numbers | Minimum degree of purity of the active substance | Date of approval | Expiry date of approval | Product type | Specific conditions |
---|
Fludioxonil | IUPAC Name:4-(2,2-difluoro-1,3-benzodioxol-4-yl)-1H-pyrrole-3-carbonitrileEC No: Not availableCAS No: 131341-86-1 | 950 g/kg | 1 April 2018 | 31 March 2028 | 7 | The authorisations of biocidal products are subject to the following conditions:- 1.The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance.
- 2.In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to industrial and professional users.
The placing on the market of treated articles is subject to the following condition:The person responsible for the placing on the market of a treated article treated with or incorporating fludioxonil shall ensure that the label of that treated article provides the information listed in the second subparagraph of Article 58(3) of Regulation (EU) No 528/2012. |
9 | The authorisations of biocidal products are subject to the following condition:The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance.The placing on the market of treated articles is subject to the following condition:The person responsible for the placing on the market of a treated article treated with or incorporating fludioxonil shall ensure that the label of that treated article provides the information listed in the second subparagraph of Article 58(3) of Regulation (EU) No 528/2012. |
10 | The authorisations of biocidal products are subject to the following condition:The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance.The placing on the market of treated articles is subject to the following condition:The person responsible for the placing on the market of a treated article treated with or incorporating fludioxonil shall ensure that the label of that treated article provides the information listed in the second subparagraph of Article 58(3) of Regulation (EU) No 528/2012. |